is tirzepatide mounjaro FDA approves new version of diabetes drug to be sold for weight loss Mounjaro is second obesity drug

Although the weight loss is considered clinically significant according to the clinical expert consulted by CADTH on this review, there is no clear evidence that this weight loss reduces the number of patients who may develop various weight-related comorbidities, including type 2 diabetes, cardiovascular disease, and osteoarthritis

This practice not only helps manage discomfort but also promotes better treatment outcomes

The brands that win will be the ones that understand what food needs to stand for when appetite isn't the starting point and design products and experiences around that

doi: 10.1073/pnas.1415675112 49 ChiouHCLinMWHsiaoPJChenCLChiaoSLinTYet al

As always, all opinions are completely my own